Glaxo wins injunction on patent rules
- Share via
Pharmaceutical company GlaxoSmithKline won a preliminary injunction stopping the U.S. Patent and Trademark Office from implementing rules to streamline the patent application process, the patent office and Glaxo said.
The rules would have gone into effect today. They would put limits on “claims,” or how an applicant defines an invention, and on “continuations,” the number of times an applicant can file for the same innovation.
Glaxo had about 100 pending patent applications that would be affected by the new rules, a company spokeswoman said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
